While anti-AChR-antibody-mediated MG has gained considerable scientific interest, therapeutic options for MG induced by antibodies against the muscle-specific tyrosine kinase (MuSK) or the low-density lipoprotein 4 (LRP4) remain limited. The gene discussed is LRP4; the disease is myasthenia gravis.